{
  "slug": "migraine",
  "title": {
    "zh": "偏頭痛：亞洲管線與全球對手",
    "en": "Migraine: Asian pipelines and global competitors"
  },
  "answer": {
    "zh": "截至 2026-11-14，亞洲偏頭痛資產包括 Brise 註冊性臨床階段的 BR005、與 AbbVie 合作的兩個未揭露臨床前項目，以及日本新日本科學旗下 Satsuma 的鼻用 dihydroergotamine 產品 Atzumi。全球比較對象包括 atogepant、eptinezumab 與 rimegepant。急性治療與預防治療分列，臨床前合作不等於人體療效證據。",
    "en": "As of 2026-11-14, Asian migraine assets include Brise’s pivotal-stage BR005, two undisclosed preclinical programs partnered by Brise and AbbVie, and Atzumi, the intranasal dihydroergotamine product from SNBL-owned Satsuma. Global comparators include atogepant, eptinezumab and rimegepant. Acute and preventive treatment are separated; a preclinical partnership is not evidence of efficacy in people."
  },
  "scope": {
    "zh": "Brise 兩個未具名項目合併為一筆合作紀錄，未虛構代號；Satsuma 為美國公司、日本母公司控制。",
    "en": "Brise’s two unnamed programs are grouped in one collaboration record without invented codes. Satsuma is US-based and controlled by a Japanese parent."
  },
  "as_of": "2026-11-14",
  "window_start": "2026-08-17",
  "window_end": "2026-11-14",
  "rows": [
    {
      "id": "mig-brise-br005",
      "company": {
        "zh": "Brise（中國）",
        "en": "Brise (China)"
      },
      "asset": "BR005",
      "asia": true,
      "mechanism": {
        "zh": "口服小分子；公告未揭露標靶",
        "en": "Oral small molecule; target not disclosed in cited release"
      },
      "stage": {
        "zh": "註冊性臨床；公告未標期別",
        "en": "Pivotal clinical trials; phase not specified in cited release"
      },
      "indication": {
        "zh": "成人偏頭痛急性治療",
        "en": "Acute migraine treatment in adults"
      },
      "route": {
        "zh": "口服",
        "en": "Oral"
      },
      "latest": {
        "zh": "11-02 公司公告列 BR005 正進行註冊性臨床；與 AbbVie 合作的 2 個臨床前項目分開。",
        "en": "The 11-02 issuer release lists BR005 in pivotal trials; it is separate from the 2 preclinical programs partnered with AbbVie."
      },
      "date": "2026-11-02",
      "sources": [
        {
          "url": "https://www.prnewswire.com/news-releases/brise-pharmaceuticals-announces-global-license-agreement-with-abbvie-to-advance-the-next-generation-of-migraine-therapies-302925660.html",
          "title": "Brise issuer release: BR005 pipeline",
          "date": "2026-11-02",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "mig-brise",
      "company": {
        "zh": "Brise（中國）／AbbVie",
        "en": "Brise (China) / AbbVie"
      },
      "asset": "Two undisclosed preclinical programs",
      "asia": true,
      "mechanism": {
        "zh": "查無已揭露標靶",
        "en": "Targets not publicly disclosed in cited release"
      },
      "stage": {
        "zh": "臨床前",
        "en": "Preclinical"
      },
      "indication": {
        "zh": "偏頭痛；細分適應症查無",
        "en": "Migraine; specific settings not disclosed"
      },
      "route": {
        "zh": "查無",
        "en": "Not disclosed"
      },
      "latest": {
        "zh": "11-02 更新 2024 年已簽合作：Brise 負責發現，AbbVie 負責全球開發與商業化；非 2026 新簽約。",
        "en": "The 11-02 update concerns an agreement entered in 2024: Brise leads discovery and AbbVie global development and commercialization; it is not a new 2026 agreement."
      },
      "date": "2026-11-02",
      "sources": [
        {
          "url": "https://www.prnewswire.com/news-releases/brise-pharmaceuticals-announces-global-license-agreement-with-abbvie-to-advance-the-next-generation-of-migraine-therapies-302925660.html",
          "title": "Brise issuer release via PRNewswire",
          "date": "2026-11-02",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "2024 年簽約，2026 年公告更新；未列未核金額",
        "en": "Agreement entered in 2024; updated in 2026; unverified amounts omitted"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "mig-satsuma",
      "company": {
        "zh": "Satsuma／新日本科學（日本母公司）",
        "en": "Satsuma / SNBL (Japanese parent)"
      },
      "asset": "STS101 / Atzumi (dihydroergotamine)",
      "asia": true,
      "mechanism": {
        "zh": "麥角類；血清素受體作用",
        "en": "Ergot derivative; serotonergic receptor activity"
      },
      "stage": {
        "zh": "美國已核准；2025-04",
        "en": "Approved in the US; 2025-04"
      },
      "indication": {
        "zh": "成人偏頭痛急性治療",
        "en": "Acute migraine treatment in adults"
      },
      "route": {
        "zh": "鼻用粉末",
        "en": "Intranasal powder"
      },
      "latest": {
        "zh": "公司新聞清單列 2026-06 AHS 摘要與 2025-04 FDA 核准公告；未據此宣稱商業上市。",
        "en": "The company lists 2026-06 AHS abstracts and 2025-04 FDA approval; this does not establish commercial launch."
      },
      "date": "2026-06",
      "sources": [
        {
          "url": "https://www.satsumarx.com/our-research/press-releases/",
          "title": "Satsuma issuer release archive",
          "date": "2026-06",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "mig-abbvie",
      "company": {
        "zh": "AbbVie",
        "en": "AbbVie"
      },
      "asset": "atogepant / Qulipta / Aquipta",
      "asia": false,
      "mechanism": {
        "zh": "CGRP 受體拮抗劑",
        "en": "CGRP receptor antagonist"
      },
      "stage": {
        "zh": "已核准產品；經期偏頭痛第三期結果",
        "en": "Approved product; Phase 3 menstrual-migraine results"
      },
      "indication": {
        "zh": "偏頭痛預防；經期研究族群另列",
        "en": "Migraine prevention; separate menstrual-migraine population"
      },
      "route": {
        "zh": "口服",
        "en": "Oral"
      },
      "latest": {
        "zh": "公布 LUNA 第三期達主要與八項排序次要終點；經期偏頭痛研究結果不等於適應症核准。",
        "en": "Reported Phase 3 LUNA met its primary and eight ranked secondary endpoints; results are not approval for menstrual migraine."
      },
      "date": "2026-09-10",
      "sources": [
        {
          "url": "https://news.abbvie.com/2026-09-10-AbbVie-Extends-Migraine-Leadership-with-Positive-Phase-3-Atogepant-Results-in-Menstrual-Migraine",
          "title": "AbbVie LUNA topline results",
          "date": "2026-09-10",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "mig-lundbeck",
      "company": {
        "zh": "靈北",
        "en": "Lundbeck"
      },
      "asset": "eptinezumab / Vyepti",
      "asia": false,
      "mechanism": {
        "zh": "抗 CGRP 抗體",
        "en": "Anti-CGRP antibody"
      },
      "stage": {
        "zh": "日本已核准",
        "en": "Approved in Japan"
      },
      "indication": {
        "zh": "成人偏頭痛預防",
        "en": "Prevention of migraine attacks in adults"
      },
      "route": {
        "zh": "靜脈",
        "en": "IV"
      },
      "latest": {
        "zh": "公司公告日本厚生勞動省核准成人偏頭痛預防適應症。",
        "en": "Announced Japanese MHLW marketing authorization for prevention of migraine attacks in adults."
      },
      "date": "2026-09-16",
      "sources": [
        {
          "url": "https://news.cision.com/h--lundbeck-a-s/r/lundbeck-receives-marketing-authorization-for-vyepti---eptinezumab--in-japan-for-the-prevention-of-m,c4396357",
          "title": "Lundbeck issuer release via Cision",
          "date": "2026-09-16",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "mig-pfizer",
      "company": {
        "zh": "輝瑞",
        "en": "Pfizer"
      },
      "asset": "rimegepant / Nurtec ODT",
      "asia": false,
      "mechanism": {
        "zh": "CGRP 受體拮抗劑",
        "en": "CGRP receptor antagonist"
      },
      "stage": {
        "zh": "美國已核准",
        "en": "Approved in the US"
      },
      "indication": {
        "zh": "成人急性偏頭痛／陣發性偏頭痛預防",
        "en": "Acute migraine / prevention of episodic migraine in adults"
      },
      "route": {
        "zh": "口服崩散錠",
        "en": "Orally disintegrating tablet"
      },
      "latest": {
        "zh": "美國標籤修訂版為 2026-04；本次未取得更晚的本產品具日期事件。",
        "en": "The cited US label is revised 2026-04; no later dated product event was verified in this review."
      },
      "date": "2026-04",
      "sources": [
        {
          "url": "https://labeling.pfizer.com/ShowLabeling.aspx?id=19036",
          "title": "Pfizer Nurtec ODT US label",
          "date": "2026-04",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    }
  ]
}
